Intralesional interferon alpha-2b therapy for Buschke-Loewenstein tumour.
A patient with a Buschke-Loewenstein tumour associated with human papillomavirus type 6/11 is reported. He was intralesionally treated with human recombinant alpha-2b interferon (9 x 10(6) IU/day) three times weekly. The tumour completely disappeared within 5 months of continuous treatment which was well tolerated. Sixteen months after completion of therapy the patient remains well and free of disease.
Tsambaos
D
D
Department of Dermatology, University of Patras, Greece.
Monastirli
A
A
Kapranos
N
N
Georgiou
S
S
Pasmatzi
E
E
Berger
H
H
D000328:Adult; D003218:Condylomata Acuminata / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006119:Groin; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins; D012074:Remission Induction; D012871:Skin Diseases / Q000473:pathology / Q000628:therapy*; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins